Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-dependent L-type calcium channel alpha-1C subunit (CaV1.2)
- Target
- CaV1.2
- Molecular classification
- Ion channel, Voltage-gated calcium channel, L-type calcium channel, Pore-forming subunit
01
Overview
The **Voltage-dependent L-type calcium channel alpha-1C subunit** (CaV1.2, encoded by the CACNA1C gene) is the main pore-forming subunit of L-type voltage-gated calcium channels. It mediates the entry of calcium ions into cells upon membrane depolarization, a process that is crucial in cardiac and smooth muscle contraction, neuronal signaling, and various forms of signal transduction. CaV1.2 channels play an essential role in excitation-contraction coupling in the heart, helping shape the cardiac action potential and enabling calcium-induced calcium release from intracellular stores. These channels are the primary targets of the dihydropyridine class of calcium channel blockers, which are widely used to treat hypertension, angina, and arrhythmias. Mutations in the CACNA1C gene are associated with a variety of cardiovascular and neuropsychiatric diseases[1][3][7][8].
- Other names
- Calcium voltage-gated channel subunit alpha1 CCACNA1CL-type calcium channel alpha-1C subunitCaV1.2
02
Mechanism of action
Blockade of L-type calcium channel (inhibits calcium influx); Decreases cardiac contractility; Vasodilation via smooth muscle relaxation; Reduction in heart rate (negative chronotropy); Antiarrhythmic effect
03
Biological functions
Calcium ion transmembrane transportExcitation-contraction coupling (particularly in cardiac muscle)Cardiac conductionRegulation of heart rateRegulating membrane potentialCalcium-induced calcium releasePositive regulation of muscle contractionSignal transduction
04
Disease associations
Cardiovascular diseaseCardiac arrhythmiaHypertensionLong QT syndromeNeuropsychiatric disorder (e.g., bipolar disorder, schizophrenia)Autism spectrum disorder
05
Safety considerations
HypotensionBradycardiaHeart blockHeart failure exacerbationEdemaDizzinessRisk of drug interactions (e.g., with beta-blockers)
06
Interacting drugs
Verapamil
7 more in the full profile.
07
Biomarkers
CACNA1C gene variants for cardiac arrhythmia riskCACNA1C gene polymorphisms associated with neuropsychiatric disease
Beyond the preview
Go deeper on Voltage-dependent L-type calcium channel alpha-1C subunit (CaV1.2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voltage-dependent L-type calcium channel alpha-1C subunit (CaV1.2).